Jazz Pharmaceuticals PLC (JAZZ)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 470,351 | 297,929 | -372,784 | -112,838 | 275,095 |
| Revenue | US$ in thousands | 4,068,950 | 3,834,200 | 3,659,370 | 3,094,240 | 2,363,570 |
| Pretax margin | 11.56% | 7.77% | -10.19% | -3.65% | 11.64% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $470,351K ÷ $4,068,950K
= 11.56%
The pretax margin of Jazz Pharmaceuticals PLC has shown fluctuations over the past five years. In December 2020, the pretax margin stood at 11.64%, indicating that the company was generating a profit before taxes. However, in December 2021 and December 2022, the pretax margins were negative at -3.65% and -10.19% respectively, signifying that the company incurred losses before taxes during these periods.
The trend reversed in December 2023, with the pretax margin improving to 7.77%, indicating a return to profitability before taxes. This positive momentum continued into December 2024, with the pretax margin increasing to 11.56%, suggesting further improvement in the company's profitability.
Overall, the pretax margin of Jazz Pharmaceuticals PLC has displayed volatility, with a mix of profitable and loss-making periods. Investors and analysts may want to monitor future financial performance closely to assess the company's ability to sustain profitability and manage costs effectively.
Peer comparison
Dec 31, 2024